Clinical trial NCT03012724: Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)
Official title: A Prospective Multicenter Double Blind Randomized Controlled Trial to Demonstrate That the Efficacy of the H7-Coil is as Good as the Efficacy of the H1-Coil Deep Transcranial Magnetic Stimulation (DTMS) in Subjects With Major Depression Disorder (MDD)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Major Depressive Disorder (MDD)
Keywords: TMS
Deep Transcranial Magnetic Stimulation
MDD
Major Depressive Disorder
Lead sponsor: Brainsway
Sponsor class: INDUSTRY
First posted: 2017-01-06
Enrollment: 106
Sex: ALL
Minimum age (years): 22
Maximum age (years): 68
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to demonstrate that the efficacy and safety of deep brain rTMS, (Transcranial Magnetic Stimulation) H7-Coil treatment as add on treatment, is as good as the FDA cleared, H1-Coil, in subjects with major depressive disorder that have been previously unsuccessfully treated with antidepressant medications.

Detailed description: This is a prospective, 6 week, double blind, randomized, controlled, multi-center trial. The study will explore the safety and efficacy of deep brain rTMS (Transcranial Magnetic Stimulation) H7-Coil treatment and demonstrate that it is as good as the FDA cleared, H1-Coil treatment as add-on for a treatment with antidepressant drugs (a bi-therapeutic treatment ) in subjects with major depressive disorder that have been previously unsuccessfully treated with antidepressant medication.

Approximately 146 subjects will be enrolled in the study. The study population consists of subjects with MDD who have failed adequate medication treatment and who are in a current depressive episode.

The patients will be of all racial, ethnic and gender categories, ranging from 22 to 68 years of age, and have HDRS-21≥20. Outpatients will be recruited from both academic and private research centers.

The study duration is 8 weeks, with a 2 week period of screening and baseline, followed by 4 weeks of 5 daily treatments and 2 weeks of biweekly treatments. Mood and mental state will be carefully monitored through standard psychological scales and assessments during the screening and baseline and throughout treatment.

Eligibility criteria: Inclusion Criteria:

* Outpatients
* Men and women 22-68 years of age
* Primary DSM-IV diagnosis of Major Depression, single or recurrent episode.
* Current depressive episode is less than 5 years duration
* The patient did not respond to at least one but not more than four antidepressant treatments in the current episode or Patients who have not completed antidepressant trials due to intolerance to therapy of 2 or more anti-depressant medications in the current episode
* Satisfactory safety screening questionnaire for transcranial magnetic stimulation
* Patients not suffering from hypo or hyper-thyroidism based on pre-study TSH level or medically stabilized
* Capable and willing to provide informed consent and able to adhere to the treatment schedule
* Patient is stable on medication for 2 month and is not expected to change medication during all study period

Exclusion Criteria:

* Individuals diagnosed by the Investigator with the following conditions (current unless otherwise stated):

  * Depression secondary to a general medical condition, or substance-induced
  * History of substance abuse or dependence within the past 6 month (except nicotine and caffeine)
  * Any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features, Bipolar disorder, Eating disorder, Obsessive compulsive disorder
  * Post-traumatic stress disorder (current or within the past year)
  * Current generalized anxiety disorder, panic disorder or social anxiety disorder
  * Presence of a personality disorder (such as antisocial, schizotypal, histrionic, borderline, narcissistic)
* Individuals with a significant neurological disorder or insult including, but not limited to:

  * Any condition likely to be associated with increased intracranial pressure
  * Space occupying brain lesion
  * Any history of seizure EXCEPT those therapeutically induced by ECT
  * History of cerebrovascular accident
  * Transient ischemic attack within two years
  * Cerebral aneurysm
  * Dementia
  * Mini Mental State Exam score of less than or equal to 24
  * Parkinson's disease
  * Huntington's chorea
  * Multiple sclerosis
  * Increased risk of seizure for any reason
  * Individuals with hearing loss
* ECT treatment within 3 months prior to the screening visit
* History of treatment with Vagus Nerve Stimulation (VNS)
* History of treatment with Deep Brain Stimulation (DBS)
* Use of any investigational drug within 4 weeks of the randomization visit
* Use of any prohibited study medication(s)
* Present suicidal risk as assessed by the investigator or significant suicide risk
* Any self-inflicted harm in the past 3 months not in the context of suicidal ideation
* Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease
* Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
* Implanted neurostimulators
* History of abnormal MRI
* Known or suspected pregnancy
* If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the rTMS trial
* Clinically significant laboratory abnormality, in the opinion of the Investigator based on CBC and biochemistry
* Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse
* Women: if pregnant, planning on becoming pregnant, or currently nursing

Primary outcomes:
measure: HDRS-21 Score Change From Baseline
timeFrame: Week 6 post randomization
Secondary outcomes:
measure: Response Rate in HDRS-21
timeFrame: Week 6 post randomization
measure: Remission Rate
timeFrame: Week 6 post randomization
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Kadima Neuropsychiatry
state: California
city: Los Angeles
country: United States
facility: CalNeuro Research Group
state: California
city: Juno Beach
country: United States
facility: Advanced Mental Health Care Inc. - Juno Beach
state: Florida
city: Palm Beach
country: United States
facility: Advanced Mental Health Care Inc. - Palm Beach
state: Florida
city: Royal Palm Beach
country: United States
facility: Advanced Mental Health Care Inc. - Royal Palm Beach
state: Florida
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
city: McLean
country: United States
facility: Greenbrook TMS NeuroHealth Centers
state: Virginia
city: Toronto
country: Canada
facility: Center for Addiction & Mental Health (CAMH)
state: Ontario
city: Be'er Sheva'
country: Israel
facility: Dr. Hadar Shalev
Study officials:
References: